Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR066 in r/r B-Cell Lymphoma Post-CD19 CAR-T
NCT04036019Phase 1Completed
- Sponsor
- Tongji Hospital
- Start
- Aug 2019
- Primary completion
- Jun 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C-CAR066 in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and 1 more, sponsored by Tongji Hospital. Primary endpoint: Incidence of adverse events at 12 weeks. Started Aug 2019; status: completed.
02
Drugs
C-CAR066
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT04036019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04036019.